Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ... Yahoo Finance: Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ... Amsterdam, The Netherlands – – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
MM&M: Takeda takes stab at CTV rare disease marketing with HyQvia campaign Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ... Argenx SE gained U.S. FDA approval of subcutaneously given Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
